In addition, the biomarker services (sample preparation, assay development, and biomarker validation and testing) and applications (drug discovery and formulation, and development of molecular diagnostics and personalized medicine) market have also been illustrated in the report. Drug discovery and development segment holds the largest share of biomarker applications market. This is attributed to the potential of biomarkers to reduce the time span of clinical trials, which ultimately decreases the overall cost of the entire drug discovery and development process.
On the basis of type of disease, the global biomarkers market is further classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis). Oncology biomarkers market accounts for the lion’s share of the biomarker disease indication market and further this market is forecast to grow at the highest growth rate in the next five years. Increasing need for the early diagnosis of tumor cells is the major factor stimulating the growth of oncology market. Oncology biomarkers enhance the screening and early detection of cancer as well as facilitate the high-speed, non-invasive cancer diagnosis procedure.
The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.)
Scope of the Report
This research report categorizes the global biomarkers market on the basis of discovery technology, services, applications, and disease indications. The
Copyright©2012 Vocus, Inc.
All rights reserved